Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Front Immunol ; 11: 692, 2020.
Article in English | MEDLINE | ID: mdl-32391011

ABSTRACT

Changing the immune responses to allergens is the cornerstone of allergen immunotherapy. Allergen-specific immunotherapy that consists of repeated administration of increasing doses of allergen extract is potentially curative. The major inconveniences of allergen-specific immunotherapy include failure to modify immune responses, long-term treatment leading to non-compliance and the potential for developing life-threating anaphylaxis. Here we investigated the effect of a novel liposomal formulation carrying low dose of allergen combined with CpG-ODN, a synthetic TLR9 agonist, on established allergic lung inflammation. We found that challenge with allergen (OVA) encapsulated in cationic liposome induced significantly less severe cutaneous anaphylactic reaction. Notably, short-term treatment (three doses) with a liposomal formulation containing co-encapsulated allergen plus CpG-ODN, but not allergen or CpG-ODN alone, reversed an established allergic lung inflammation and provided long-term protection. This liposomal formulation was also effective against allergens derived from Blomia tropicalis mite extract. The attenuation of allergic inflammation was not associated with increased numbers of Foxp3-positive or IL-10-producing regulatory T cells or with increased levels of IFN-gamma in the lungs. Instead, the anti-allergic effect of the liposomal formulation was dependent of the innate immune signal transduction generated in CD11c-positive putative dendritic cells expressing MyD88 molecule. Therefore, we highlight the pivotal role of dendritic cells in mediating the attenuation of established allergic lung inflammation following immunotherapy with a liposomal formulation containing allergen plus CpG-ODN.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Allergens/administration & dosage , Asthma/immunology , Dendritic Cells/immunology , Desensitization, Immunologic/methods , Drug Delivery Systems/methods , Myeloid Differentiation Factor 88/metabolism , Oligodeoxyribonucleotides/administration & dosage , Signal Transduction/drug effects , Allergens/adverse effects , Anaphylaxis/immunology , Anaphylaxis/prevention & control , Animals , Asthma/chemically induced , Disease Models, Animal , Female , Gene Knockout Techniques , Liposomes , Mice , Mice, Inbred C57BL , Mice, Knockout , Myeloid Differentiation Factor 88/genetics , Treatment Outcome
2.
J Diabetes Res ; 2018: 6209694, 2018.
Article in English | MEDLINE | ID: mdl-30426021

ABSTRACT

Paracoccidioidomycosis, a key issue for Brazilian health service, can be aggravated in patients with impaired immunological responses, such as diabetic patients. We evaluated the role of insulin in inflammatory parameters in diabetic and nondiabetic mice using a systemic mycosis Paracoccidioides brasiliensis (Pb) model. Diabetic C57BL-6 mice and controls were infected with Pb18 and treated with insulin for 12 days prior to experiments. After 55 days, infected diabetic mice exhibited fewer leukocytes in both peritoneal lavage fluid (PeLF) and bronchoalveolar lavage fluid and reduced secretion of interleukin- (IL-) 6 in lungs. In addition, diabetic mice presented a reduced influx of TCD4+ cells, TCD8+ cells, B lymphocytes, NK cells, and dendritic cells compared to control infected groups. Insulin treatment restored the leukocyte number in PeLF and restored the presence of B lymphocytes, dendritic cells, and NK cells in lungs of diabetic animals. The data suggest that diabetic mice present impaired immunological response to Pb18 infection and insulin modulates inflammation by reducing IL-6 levels in lung and CINC-1 levels in spleen and liver homogenates, restoring leukocyte concentrations in PeLF and also restoring populations of dendritic cells and B lymphocytes in lungs of diabetic mice, permitting the host to better control the infection.


Subject(s)
B-Lymphocytes/drug effects , Dendritic Cells/drug effects , Hypoglycemic Agents/therapeutic use , Inflammation/drug therapy , Insulin/therapeutic use , Killer Cells, Natural/drug effects , Lung/drug effects , Paracoccidioidomycosis/drug therapy , Animals , Diabetes Mellitus, Experimental/drug therapy , Hypoglycemic Agents/pharmacology , Insulin/pharmacology , Male , Mice , Mice, Inbred C57BL , Paracoccidioides
3.
Inflamm Res ; 62(8): 733-42, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23665851

ABSTRACT

OBJECTIVE AND DESIGN: Antithrombin is known as the most important natural coagulation inhibitor and has been shown to have anti-inflammatory properties. The present study aimed to investigate the effects of Bothrops jararaca antithrombin on acute inflammation induced by carrageenan in mice. METHODS: We evaluated the anti-inflammatory activity of antithrombin on models of paw edema formation, cell migration and leukocyte-endothelium interaction in mice (Swiss; n = 5). Acute inflammation was induced by the administration of carrageenan (15 mg kg⁻¹). RESULTS: Treatment with B. jararaca antithrombin (1 mg kg⁻¹) 1 h before or after carrageenan administration significantly inhibited paw edema formation, reduced cell influx to the peritoneal cavity due to reduction in the migration of polymorphonuclear cells, and attenuated leukocyte rolling in the microcirculation of the cremaster muscle.The effects of antithrombin on vascular and cellular events of inflammation were completely abolished by treatment with the cyclo-oxygenase inhibitor indomethacin (4 mg kg⁻¹), suggesting the involvement of prostacyclin in the mechanism of inflammation inhibition by B. jararaca antithrombin. CONCLUSION: This work showed for the first time the anti-inflammatory properties of B. jararaca antithrombin on vascular and cellular events of inflammation. These findings suggest that antithrombin is effective in preventing paw edema formation, cell migration and leukocyte rolling induced by carrageenan in mice.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Antithrombins/therapeutic use , Bothrops , Edema/drug therapy , Animals , Antithrombins/isolation & purification , Carrageenan , Cell Movement/drug effects , Cyclooxygenase Inhibitors/pharmacology , Edema/chemically induced , Edema/physiopathology , Endothelium, Vascular/physiology , Foot , Indomethacin/pharmacology , Leukocytes/physiology , Male , Mice , Peritoneal Cavity/cytology
SELECTION OF CITATIONS
SEARCH DETAIL
...